Adoptive immunotherapy with adherent lymphokine-activated killer (A-LAK) cells in glioblastoma multiforme.

Authors :: Munari L
Silvani A
Passerini CG
Radrizzani M
Parmiani G
Boiardi A
Source :: Journal of neurosurgical sciences [J Neurosurg Sci] 1990 Jul-Dec; Vol. 34 (3-4), pp. 283-8.
Publication Year :: 1990
Abstract: Adherent lymphokine-activated killer (A-LAK) activity has been recently differentiated in recombinant interleukin-2 (rIL-2) activated PBL. A pilot study on A-LAK + rIL-2 injection into the post-surgical cavity of glioblastoma-operated patients is ongoing. Preliminary data support the feasibility of this technique, which may improve the antitumor response of the host.

Subjects :: Adult
Combined Modality Therapy
Feasibility Studies
Humans
Interleukin-2 therapeutic use
Male
Recombinant Proteins therapeutic use
Brain Neoplasms therapy
Glioblastoma therapy
Immunotherapy, Adoptive methods
Killer Cells, Lymphokine-Activated transplantation

Tools